Can Lifecore Biomedical, Inc. (LFCR) Unlock Long-Term Value Through Expanding Biopharma Collaborations?
TheFly reported on June 16 that Barrington increased its price target on LFCR to $6.50 from $6.00 while reaffirming an Outperform rating on the shares.


